Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
Cathie Wood’s ARK ETFs have reported their daily trades for Wednesday, March 26th, 2025, with a notable focus on the biotechnology sector. The most significant trade of the day was the purchase of 899,272 shares of Pacific Biosciences of California Inc (NASDAQ:PACB), amounting to a total dollar value of $1,178,046. This move underscores ARK’s continued interest in the genomics space, as PACB has been a recurring buy in recent days, including substantial acquisitions on the previous Friday and Monday.
In contrast, ARK opted to reduce its holdings in two other companies. ARK’s ARKG ETF sold 118,041 shares of Repare Therapeutics Inc (NASDAQ:RPTX), valued at $121,582, continuing a sell-off pattern observed over the past week. Additionally, ARK’s ARKX (NYSE:ARKX) ETF divested 424 shares of ANSYS Inc (NASDAQ:ANSS), totaling $138,508.
The daily report also highlighted ARK’s investment in AeroVironment Inc (NASDAQ:AVAV), with a combined purchase of 1,187 shares through its ARKQ and ARKX ETFs, amounting to $155,734. This trade suggests a growing interest in the aerospace sector, complementing the fund’s technology and genomics-focused portfolio.
Investors watching ARK’s trading patterns may find the consistent buying of Pacific Biosciences shares particularly noteworthy, indicating a strong conviction in the company’s long-term potential. Meanwhile, the sales of Repare Therapeutics could signal a strategic shift or a response to market conditions.
The daily trades, encompassing both buys and sells across various sectors, reflect ARK’s active management strategy and commitment to investing in what they believe to be disruptive innovation. As ARK continues to adjust its holdings, investors and market watchers alike will be keen to follow these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.